Martell Bridget A 4

What Happened

• Bridget A. Martell, a director of Aligos Therapeutics, received an equity award on 2026-06-25 covering 5,860 shares. The grant is reported as a derivative award (option-like) with an acquisition price of $0.00, so no cash was paid at grant. This was an award/compensation transaction rather than a market purchase or sale.

Key Details

• Transaction date: 2026-06-25; Filing date: 2026-06-29 (file appears to be late relative to the 2-business-day reporting window).
• Transaction type/code: A (Grant/award/other acquisition); Derivative security covering 5,860 shares at $0.00.
• Shares owned after transaction: Not stated in the provided excerpt of the filing.
• Footnote: The award vests 100% on the earlier of the first anniversary of the grant date or immediately prior to the Issuer's 2027 annual meeting, subject to continuous service.
• No exercise or sale occurred — this is a grant of a compensatory equity award, not a cash exercise or market transaction.

Context

• This appears to be a routine director compensation award. For derivative grants like this, value is typically realized only if the option vests and the holder exercises and/or sells shares later. The filing does not indicate exercise, sale, or use of any 10b5-1 plan.